These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38795314)

  • 1. Ensitrelvir Fumaric Acid: First Approval.
    Syed YY
    Drugs; 2024 Jun; 84(6):721-728. PubMed ID: 38795314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacological characteristics and clinical study results of ensitrelvir fumaric acid (XOCOVA
    Tsuge Y; Ariwa Y; Shibata K
    Nihon Yakurigaku Zasshi; 2024; 159(4):264-281. PubMed ID: 38945910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ensitrelvir in patients with SARS-CoV-2: A retrospective chart review.
    Yamato M; Kinoshita M; Miyazawa S; Seki M; Mizuno T; Sonoyama T
    J Infect Chemother; 2024 Sep; 30(9):946-950. PubMed ID: 38367932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, Tolerability, and Pharmacokinetics of the Novel Antiviral Agent Ensitrelvir Fumaric Acid, a SARS-CoV-2 3CL Protease Inhibitor, in Healthy Adults.
    Shimizu R; Sonoyama T; Fukuhara T; Kuwata A; Matsuo Y; Kubota R
    Antimicrob Agents Chemother; 2022 Oct; 66(10):e0063222. PubMed ID: 36094202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment with ensitrelvir for COVID-19 in hospitalized patients of very advanced age: Case series.
    Tomita T; Miyazawa S; Sonoyama T
    Medicine (Baltimore); 2024 Jul; 103(30):e39080. PubMed ID: 39058834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sporadic Occurrence of Ensitrelvir-Resistant SARS-CoV-2, Japan.
    Doi A; Ota M; Saito M; Matsuyama S
    Emerg Infect Dis; 2024 Jun; 30(6):1289-1291. PubMed ID: 38669127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prophylactic effect of ensitrelvir in mice infected with SARS-CoV-2.
    Nobori H; Baba K; Kuroda T; Baba K; Matsumoto K; Yoshida S; Watari R; Tachibana Y; Kato T; Fukao K
    Antiviral Res; 2024 Apr; 224():105852. PubMed ID: 38428748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ensitrelvir as a potential treatment for COVID-19.
    McCarthy MW
    Expert Opin Pharmacother; 2022 Dec; 23(18):1995-1998. PubMed ID: 36350029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Computational Estimation of Residues Involving Resistance to the SARS-CoV-2 Main Protease Inhibitor Ensitrelvir Based on Virtual Alanine Scan of the Active Site.
    Mizuno A; Nakayoshi T; Kato K; Kurimoto E; Oda A
    Biol Pharm Bull; 2024; 47(5):967-977. PubMed ID: 38763751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Ensitrelvir for Asymptomatic or Mild COVID-19: An Exploratory Analysis of a Multicenter, Randomized, Phase 2b/3 Clinical Trial.
    Ohmagari N; Yotsuyanagi H; Doi Y; Yamato M; Imamura T; Sakaguchi H; Yamanaka H; Imaoka R; Fukushi A; Ichihashi G; Sanaki T; Tsuge Y; Uehara T; Mukae H
    Influenza Other Respir Viruses; 2024 Jun; 18(6):e13338. PubMed ID: 38890511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation and evaluation of protease inhibitor-resistant SARS-CoV-2 strains.
    Bouzidi HS; Driouich JS; Klitting R; Bernadin O; Piorkowski G; Amaral R; Fraisse L; Mowbray CE; Scandale I; Escudié F; Chatelain E; de Lamballerie X; Nougairède A; Touret F
    Antiviral Res; 2024 Feb; 222():105814. PubMed ID: 38272321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part.
    Mukae H; Yotsuyanagi H; Ohmagari N; Doi Y; Imamura T; Sonoyama T; Fukuhara T; Ichihashi G; Sanaki T; Baba K; Takeda Y; Tsuge Y; Uehara T
    Antimicrob Agents Chemother; 2022 Oct; 66(10):e0069722. PubMed ID: 36098519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of Coproporphyrin-I Determination in First-in-Human Study for Early Evaluation of OATP1B Inhibitory Potential Based on Investigation of Ensitrelvir, an Oral SARS-CoV-2 3C-Like Protease Inhibitor.
    Watari R; Sawada H; Hashimoto H; Kasai Y; Oka R; Shimizu R; Matsuzaki T
    J Pharm Sci; 2024 Mar; 113(3):798-805. PubMed ID: 37742997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of ensitrelvir for cough due to COVID-19 Omicron variant in medical healthcare workers.
    Miyashita N; Nakamori Y; Ogata M; Fukuda N; Yamura A; Ito T
    Antimicrob Agents Chemother; 2024 Oct; 68(10):e0106424. PubMed ID: 39207153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of post COVID-19 condition by early treatment with ensitrelvir in the phase 3 SCORPIO-SR trial.
    Yotsuyanagi H; Ohmagari N; Doi Y; Yamato M; Fukushi A; Imamura T; Sakaguchi H; Sonoyama T; Sanaki T; Ichihashi G; Tsuge Y; Uehara T; Mukae H
    Antiviral Res; 2024 Sep; 229():105958. PubMed ID: 38972603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ensitrelvir eradicates persistent SARS-CoV-2 infection in a follicular lymphoma patient treated with anti-CD20 antibodies.
    Sakamaki I; Negoro E; Iwasaki H; Yamauchi T
    J Infect Chemother; 2024 Feb; 30(2):147-149. PubMed ID: 37690521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic and Pharmacodynamic Analysis of the 3CL Protease Inhibitor Ensitrelvir in a SARS-CoV-2 Infection Mouse Model.
    Fukao K; Nobori H; Kuroda T; Baba K; Matsumoto K; Tanaka Y; Tachibana Y; Kato T; Shishido T
    Viruses; 2023 Oct; 15(10):. PubMed ID: 37896829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of 5-Day Oral Ensitrelvir for Patients With Mild to Moderate COVID-19: The SCORPIO-SR Randomized Clinical Trial.
    Yotsuyanagi H; Ohmagari N; Doi Y; Yamato M; Bac NH; Cha BK; Imamura T; Sonoyama T; Ichihashi G; Sanaki T; Tsuge Y; Uehara T; Mukae H
    JAMA Netw Open; 2024 Feb; 7(2):e2354991. PubMed ID: 38335000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the Drug-Drug Interaction Potential of Ensitrelvir Fumaric Acid with Cytochrome P450 3A Substrates in Healthy Japanese Adults.
    Shimizu R; Sonoyama T; Fukuhara T; Kuwata A; Matsuzaki T; Matsuo Y; Kubota R
    Clin Drug Investig; 2023 May; 43(5):335-346. PubMed ID: 37171749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of ensitrelvir against SARS-CoV-2 in a delayed-treatment mouse model.
    Nobori H; Fukao K; Kuroda T; Anan N; Tashima R; Nakashima M; Noda S; Tajiri M; Torii M; Toba S; Uemura K; Sanaki T; Shishido T; Tachibana Y; Kato T
    J Antimicrob Chemother; 2022 Oct; 77(11):2984-2991. PubMed ID: 35914182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.